The effect of N-acetylcysteine in GAD

Phase 3

Recruiting

• Conditions: Generalized anxiety disorder.; Generalized anxiety disorder; F41.1

• Registration Number: IRCT20150706023083N5
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients with GAD disorder at the discretion of a psychiatrist based on DSM-V criteria and Spit-zer questionnaire

Exclusion Criteria

Patients with hepatic encephalopathy , asthma, gastric hemorrhage and fluid overload
Taking anticonvulsant drugs
Other Mental disorders such as autism, seizures and chronic diseases
Pregnant and lactating women
Inability to understand and sign consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Anxiety score. Timepoint: On arrival and after 2, 4, 6, 8 weeks after receiving medicine. Method of measurement: Spit-Zer Anxiety Questionnaire.